CHAMPIONS ONCOLOGY, INC.
About CHAMPIONS ONCOLOGY, INC.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $56.9M
- Net income
- $4.7M
- Total assets
- $32.3M
- Market cap
- $78.5M
- Gross margin
- 50.1%
- Operating margin
- 8.0%
- Net margin
- 8.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $56.9M
- Cost of revenue
- $28.4M
- Gross profit
- $28.6M
- Operating expenses
- $24.0M
- Operating income
- $4.6M
- Income tax
- -$75.0K
- Net income
- $4.7M
- EPS (basic)
- $0.34
- EPS (diluted)
- $0.33
Balance sheet
- Total assets
- $32.3M
- Current assets
- $22.4M
- Total liabilities
- $28.6M
- Current liabilities
- $23.9M
- Shareholders’ equity
- $3.8M
Cash flow
- Operating cash flow
- $7.4M
- Investing cash flow
- -$389.0K
- Financing cash flow
- $170.0K
- Net cash flow
- $7.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $78.5M
- P/E ratio
- 17.1
- EPS (diluted)
- $0.33
- Shares outstanding
- 13.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 31, 1994
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $4.7M in FY2025.
- Revenue grew 39% from FY2021 to FY2025.
- Gross margin of 50.1%, net margin 8.3%.
- Trading 37% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 17.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CHAMPIONS ONCOLOGY, INC..
Write a review
News about CHAMPIONS ONCOLOGY, INC.
News & sentiment via Polygon.io
